Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
PARIS - Sequans Communications S.A. (NYSE:SQNS) announced Monday the appointment of Jason W. Cohenour to its Board of Directors as the cellular IoT semiconductor company seeks to strengthen its leadership team.
Cohenour brings over 30 years of executive leadership experience, most notably serving as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018. During his tenure at Sierra Wireless, he led a strategic transformation that established the company as a global player in the Internet of Things market and grew company revenues to nearly $800 million.
Prior to his CEO role, Cohenour held several senior positions at Sierra Wireless between 1996 and 2005, including Vice President of Sales and Chief Operating Officer.
Currently, Cohenour serves as Lead Independent Director at Blackline Safety (TSX:BLN) and has previously held board positions at Lantronix (NASDAQ:LTRX), CalAmp (NASDAQ:CAMP) - which according to InvestingPro data has seen significant challenges with its stock down over 85% in the past year - and RF Industries (NASDAQ:RFIL). CalAmp’s current market capitalization stands at approximately $31 million, with analysts maintaining positive expectations for sales growth in the current year.
"We are delighted to welcome Jason to our board," said Georges Karam, CEO of Sequans, in the company’s press release. "His deep industry expertise and proven leadership will be instrumental as we accelerate our growth." This appointment comes at a crucial time for the industry, where companies like CalAmp face significant market challenges. InvestingPro offers detailed analysis of similar companies in the IoT space, with over 10 additional ProTips available for CalAmp alone.
Sequans also announced that Dominique Pitteloud is departing the board after 20 years of service.
Founded in 2003, Sequans Communications specializes in wireless cellular technology for the Internet of Things, offering LTE-M/NB-IoT, 4G LTE, and 5G NR platforms.
In other recent news, Wedbush analyst Yun Zhong initiated coverage on CAMP4 Therapeutics Corp, assigning the stock an Outperform rating and setting a price target of $8.00. Zhong highlighted CAMP4’s proprietary RNA-based technology platform, which is designed to address haploinsufficient diseases that currently lack effective treatments. The analyst noted that preclinical data from two of CAMP4’s programs focusing on genetic metabolic and central nervous system disorders have demonstrated solid proof of mechanism. Despite a decline in CAMP4’s share price since its initial public offering in October 2024, Zhong believes the company has not experienced any fundamental changes. The Outperform rating suggests that Wedbush expects CAMP4’s stock to outperform the average return of stocks covered by the firm. Zhong’s analysis indicates optimism that emerging clinical data could enhance investor sentiment toward CAMP4 Therapeutics. The $8.00 price target reflects Wedbush’s confidence in the potential upside for the stock, based on the promising nature of CAMP4’s technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.